High-performance liquid chromatography ionspray mass spectrometry for the specific determination of digoxin and some related cardiac glycosides in human plasma

被引:63
作者
Tracqui, A
Kintz, P
Ludes, B
Mangin, P
机构
[1] Inst. de Med. Légale, 67085 Strasbourg Cedex
来源
JOURNAL OF CHROMATOGRAPHY B | 1997年 / 692卷 / 01期
关键词
digoxin; digitoxin; lanatoside; acetyldigitoxin;
D O I
10.1016/S0378-4347(96)00462-8
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
An original method based upon high-performance liquid chromatography coupled to ionspray mass spectrometry (HPLC-ISP-MS) has been developed for the identification and quantification in plasma of several cardiac glycosides, namely digoxin, digitoxin, lanatoside C and acetyldigitoxin. After single-step liquid-liquid extraction by chloroform-2 propanol (95:5, v/v) at pH 9.5 using oleandrin as an internal standard, solutes are separated on a 4 mu m NovaPak C-18 (Waters) column (150x2.0 mm, I.D.), using a gradient of acetonitrile-2 mM NH4COOH, pH 3 buffer (flow-rate 200 mu 1/min, post-column split 1:3). Detection is done by a Perkin-EImer Sciex API-100 mass analyzer equipped with an ISP interface. In most instances the major ion observed is not [M+H](+) as expected, but [M+NH4](+). The mean retention times (min) an: lanatoside C, 5.74; digoxin, 6.00; digitoxin, 8.08, oleandrin, 8.30, acetyldigitoxin, 8.66 and 9.01 (isomers alpha and beta, respectively). The lower limits of detection in single ion monitoring mode range from 0.15 ng/ml (alpha- and beta-acetyldigitoxin) to 0.60 ng/ml (lanatoside C), making the method less sensitive than radioimmunoassay, whereas it is much mon specific.
引用
收藏
页码:101 / 109
页数:9
相关论文
共 27 条
[1]  
ADERJAN R, 1979, ARCH TOXICOL, V42, P107
[2]  
[Anonymous], 1995, DISPOSITION TOXIC DR
[3]  
DOERGE DR, 1993, 208 FIS INSTR
[4]  
EATON AN, 1995, INT LAB, V25, P18
[5]  
ELLENHORN MJ, 1988, MED TOXICOLOGY DIAGN, P200
[6]  
FLESCH F, 1989, LET PHYTOTHER PHARM, V11, P7
[7]  
FROHNE D, 1987, GIFTPFLANZEN HDB APO, P51
[8]  
GARTEIZ D, 1993, 2350917734E MS HEWL
[9]  
GODFRAIND T, 1989, PHARM CONCEPTS FONDA, P167
[10]  
GRAVES SW, 1986, CLIN CHEM, V32, P1506